The total number of shares outstanding for the Company was 24,118,424 as at March 6, 2008.
Notice of Annual General Meeting
Spectral will hold its Annual General Meeting of Shareholders at 4:00 PM on May 13, 2008 at the offices of Stikeman, Elliott LLP, Suite 5300, 199 Bay Street, Toronto, Ontario.
About Spectral Diagnostics
Spectral is a developer of innovative technologies for comprehensive disease management. Spectral's lead product is its EAA(TM) Endotoxin Activity Assay, the only FDA approved diagnostic for the measurement of endotoxin. Spectral technologies provide accurate and timely information to clinicians enabling the early initiation of appropriate and targeted therapy. Spectral is listed on TSX under the symbol SDI.
Information in this news release that is not current or historical
factual information may constitute forward-looking information within the
meaning of securities laws. Implicit in this information, particularly in
respect of the future outlook of Spectral and anticipated events or
results, are assumptions based on beliefs of Spectral's senior management
as well as information currently available to it. While these assumptions
were considered reasonable by Spectral at the time of preparation, they may
prove to be incorrect. Readers are cautioned that actual results are
subject to a number of risks and uncertainties, including the availability
of funds and resources to pursue R&D projects, the successful and timely
completion of clinical studies, the ability of Spectral to take advantage
of business opportunities in the biomedical industry, the granting of
necessary approvals by regulatory authorities as well as general economic,
market and business conditions, and could differ materially from what is
The TSX has not reviewed and does not accept responsibility for the
|SOURCE Spectral Diagnostics Inc.|
Copyright©2008 PR Newswire.
All rights reserved